3H-Imidazo<4,5-c>pyridin-2-carbaldehyd, monomer | 56805-25-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 3H-Imidazo<4,5-c>pyridin-2-carbaldehyd, monomer
• 英文别名: 1(3)H-imidazo[4,5-c]pyridine-2-carbaldehyde；1H-Imidazo[4,5-c]pyridine-2-carbaldehyde；3H-imidazo[4,5-c]pyridine-2-carbaldehyde
• CAS: 56805-25-5
• 化学式: C₇H₅N₃O
• 分子量: 147.136
• InChiKey: AYHPZVWSPSNAJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0388909A2

  公开（公告）日：1990-09-26

  A compound of the formula : wherein A is iower alkylene or carbonyl, R¹ and R² are each halogen, lower alkyloxy, lower alkylthio or lower alkylsulfinyl, R³ is amino-protective group, and R⁴ is hydrogen, lower alkyl which may have heterocyclic group, piperidyl which may have suitable substituent(s), amidino or amino-protective group, and pharmaceutically acceptable salt thereof, processes for their preparation and pharmaceutical compositions comprising them as an active ingredient.

  式中的化合物 其中 A 是烯烃或羰基、 R¹ 和 R² 分别为卤素、低级烷氧基、低级烷硫基或低级烷基亚磺酰基、 R³ 是氨基保护基团，以及 R⁴ 是氢、可带有杂环基的低级烷基、可带有适当取代基的哌啶基、脒基或氨基保护基、 及其药学上可接受的盐、 它们的制备工艺和含有它们作为活性成分的药物组合物。
• HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2673269A1

  公开（公告）日：2013-12-18
• US5145860A
  申请人：——

  公开号：US5145860A

  公开（公告）日：1992-09-08
• US5229386A
  申请人：——

  公开号：US5229386A

  公开（公告）日：1993-07-20
• [EN] HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE PI3 KINASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012107465A1

  公开（公告）日：2012-08-16

  Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.